Important considerations for the referral of patients with severe aortic stenosis

In this recorded webinar hear from leading cardiologist Dr. Shrilla Banerjee on:

What sort of service does she want for her patients
Which patients should be referred
The ideal patient pathway
Barriers to the adoption of TAVI
A new tool for the referral process that includes assessment of frailty

Speaker

In the new publication from GIRFT (Get It Right First Time) “to ensure that serial referrals are avoided and that all relevant treatment options are considered, each tertiary centre should have a single point of entry into a pathway for the assessment of patients referred for consideration of intervention for severe aortic valve disease and another for the assessment of severe mitral/tricuspid disease. Referrals should be made to the relevant heart team rather than to an individual cardiologist or surgeon¹.”

Hear more from Dr. Shrilla Banerjee on her view of the perfect referral pathway.

More about the 2021 ESC/EACTS ESC Guidelines

Check our latest articles

View all articles

Stay informed with our newsletter

For signing up to the monthly Edwards Lifesciences TAVI newsletter. You will now receive emails on the latest developments and industry insights on aortic stenosis

Terms and conditions

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.

Our monthly updates provide you the latest developments in TAVI and aortic stenosis. Read more

References

1Clarke, S and Ray, S (2021) GIRFT Programme National Specialty Report, Cardiology pg 38. Available at: https://www.gettingitrightfirsttime.co.uk/wp-content/uploads/2021/02/Cardiology-10-03i-EMBARGOED.pdf

Share this page on:

Latest Developments

Treatment & Guidelines

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER 3, SAPIEN, and SAPIEN 3 are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

Important considerations for the referral of patients with severe aortic stenosis

Check our latest articles

Stay informed with our newsletter

Thank you!

References

Help us create better content with 3 short questions.